IBRX270416C00006000
IBRX Apr 16 2027 6.00 Call
optionOPRA
InactiveSep 22, 2026
3.90USD+30.000%(+0.90)1Vol0OI
Loading…
Underlying
Underlying Price
$8.36
Type
Call
Strike
6
Expiration
Apr 16, 2027
DTE
178d
Moneyness
ITM
Intrinsic
$2.36
IBRX 6 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $4.53 | +0.00% | 1 | 5 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $3.50 | -12.50% | 53 | 147 |
| Nov 27, 2026 | 38d | $3.92 | +0.00% | 2 | 1 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Mar 19, 2027 | 150d | $4.45 | -3.26% | 2 | 17 |
| Apr 16, 2027 | 178d | $3.90 | +30.00% | 1 | 0 |
| May 21, 2027 | 213d | $3.30 | +0.00% | 1 | 1 |
IBRX Nearby Strikes · Apr 16, 2027
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.